Adimab LLC:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3034)
◆英語タイトル:Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3034
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Adimab LLC (Adimab) is an antibody discovery technology provider that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, infectious disease, and others. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs, among others. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Adimab Raises US$13.8 Million In Series F Financing 12
Partnerships 14
Adimab Enters into Agreement with Boehringer Ingelheim 14
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Licensing Agreements 35
Eli Lilly Enters into Licensing Agreement with Adimab 35
Arsanis Enters into Licensing Agreement with Adimab 36
Kite Pharma Exercises Option for Licensing Agreement with Adimab 37
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38
Adimab Enters into Licensing Agreement with Merck 39
Adimab Enters Into Licensing Agreement With Novo Nordisk 40
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab LLC – Key Competitors 44
Adimab LLC – Key Employees 45
Adimab LLC – Locations And Subsidiaries 46
Head Office 46
Recent Developments 47
Other Significant Developments 47
Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 47
Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 49
Jan 08, 2018: Adimab Provides Year-End Update on 2017 Partnership Activities 50
Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab Raises US$13.8 Million In Series F Financing 12
Adimab Enters into Agreement with Boehringer Ingelheim 14
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Eli Lilly Enters into Licensing Agreement with Adimab 35
Arsanis Enters into Licensing Agreement with Adimab 36
Kite Pharma Exercises Option for Licensing Agreement with Adimab 37
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 38
Adimab Enters into Licensing Agreement with Merck 39
Adimab Enters Into Licensing Agreement With Novo Nordisk 40
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 41
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab LLC, Key Competitors 44
Adimab LLC, Key Employees 45

List of Figures
Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Adimab LLC:製薬・医療:M&Aディール及び事業提携情報(Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆